论文部分内容阅读
目的观察长效干扰素聚乙二醇干扰素(PEG-IFN)α-2 a与普通干扰素(IFN)α-1b治疗慢性丙型肝炎(CHC)的临床疗效及安全性。方法60例CHC患者分别采用PEG-IFNα-2 a和IFNα-1b联合应用利巴韦林治疗,疗程48周,24周后随访。观察两组在病毒学应答和生化学应答以及药物不良反应方面的差异。结果长效干扰素组的病毒学应答率和生化应答均优于普通组,长效干扰素组的ETVR、SVR分别是73.3%和46.7%明显高于普通干扰素组的43.3%和26.7%,差异有统计学意义(P<0.05);停药时长效干扰素组ALT恢复正常比例高于普通组;两组患者有相似的不良反应,但脱发和甲状腺功能异常的发生率PEG-IFNα-2 a组高于IFNα-1b组(P<0.05)。结论PEG-IFNα-2 a对CHC患者的疗效优于IFNα-1b,但长效干扰素在用药不良反应方面较普通干扰素稍重。
Objective To observe the clinical efficacy and safety of pegylated interferon (PEG-IFN) α-2 a and interferon α-1b in the treatment of chronic hepatitis C (CHC). Methods 60 patients with CHC were treated with PEG-IFNα-2a and IFNα-1b in combination with ribavirin for 48 weeks and 24 weeks respectively. The differences in virological and biochemical responses and adverse drug reactions between the two groups were observed. Results The virologic response rate and biochemical response of the long-acting interferon group were better than that of the normal group. The ETVR and SVR of the long-acting interferon group were 73.3% and 46.7%, respectively, significantly higher than that of the common interferon group (43.3% and 26.7% The difference was statistically significant (P <0.05); discontinuation of long-acting interferon ALT recovery rate was higher than the normal group; two groups of patients with similar adverse reactions, but the incidence of hair loss and thyroid dysfunction, PEG-IFNα-2 Group a was higher than IFNα-1b group (P <0.05). Conclusion PEG-IFNα-2 a is superior to IFNα-1b in CHC patients, but the long-acting interferon is slightly heavier than normal interferon in adverse drug reactions.